Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
KymriahⓇ - CAR-T therapy
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT03876769 CASSIOPEIA (CCTL019G2201J)
1st line high risk acute lymphoblastic leukemia (ALL)
Phase 2
160
Disease Free Survival (DFS)
Single-arm study of tisagenlecleucel
Pediatric and young adult patients with 1st line high risk ALL
Arms Intervention
Target Patients
Read-out Milesstone(s)
2025
Publication
TBD
106 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation